PROFESSIONAL INTERESTS:
Interventional Cardiology & Diagnostic Cardiac Catheterization
- Femoral and Trans-Radial Artery Coronary Angiography and Interventions
- Primary PCI for STEMI
- IVUS, FFR, IFR
- Orbital, Rotational and Directional Atherectomy
- SVG Intervention with distal protection
- Hemodynamic support
- Vascular Closure devices
- Emerging Interventional Techniques
Cardiac Rehabilitation and Wellness
Nuclear Cardiology
Transthoracic, Transesophageal and 3-D Echocardiography, CIMT
Stress Echocardiography and Exercise Treadmill Testing
Congestive Heart Failure
Cardiac Rhythm Management: Pacemaker/ICD/ILR Implantation and Follow-up
Electronic Health Records, Medical Informatics
ADMINISTRATION:
Longs Peak Hospital Pharmacy & Therapeutics Committee 2017
Harbor Heart, Founder and President 2007-2017
St. Jude Medical Center, Medical Director,
Intensive (Omish) Cardiac Rehab 2015-2017
St. Jude Medical Center,
Medical Director,
Outpatient Cardiac Rehabilitation 2013-2017
St. Jude Medical Center Physician Informatics Advisory Committee 2013-2016
St. Jude Medical Center Physician Wellness Committee 2009
St. Jude Medical Center Medical Staff Quality Review Committee, Vice-Chair 2008
St. Jude Medical Center Cardiothoracic Department,
Chairman 2006, 2007
St. Jude Medical Center Executive Medical Committee 2006-2007
St. Jude Medical Center Quality Committee 2006-2007
St. Jude Medical Center Credentials Committee 2006-2007
St. Jude Medical Center Cardiothoracic Executive Committee (CTEC), 2006-2007
St. Jude Medical Center Physician Advisory Council 2005-2007
St. Jude Medical Center Pharmacy and Therapeutics Committee 2005-2007
St. Jude Medical Center Judicial Review Committee, Chairman 2005
St. Jude Medical Center Leadership Council 2005-2008
St. Jude Medical Center Cardiology Department Quality Review Committee (QRC) 2001-2017
St. Jude Medical Center Critical Care Committee 1999-2001
St. Jude Medical Center Cardiology Department QM Committee 1998-2008
St. Jude Medical Center Cardiac Cath Lab Planning Committee 1998-2008
St. Jude Medical Center Institutional Review Board 1999
St. Joseph Heritage Healthcare North Orange County Division
Finance Committee Board of Directors 2002-2007
St. Jude Heritage Medical Group Board of Directors 2004-2007
1st Vice President 2005-2007
St. Jude Heritage Medical Group Executive Committee 1998-2005
ADVISORY BOARD(S):
Leonhardt Launchpads by Cal-X Stars Business Accelerator, Inc & Second Heart Assist, Inc
520 Broadway, Suite 200, Santa Monica, CA 90401
BIBLIOGRAPHY:Publications
1. Sherman, J.R., and Weinberg, R.B. Serum Apolipoprotein A-IV and Lipoprotein Cholesterol inPatients Undergoing Total Parenteral Nutrition.
Gastroenterology, 95:394-401, 1988.
2. Sherman, J.R. and Anwar, A. et al. Distal Vessel Pullback Angiography and Pressure GradientMeasurement: An Innovative Diagnostic Approach to the
No-reow
Phenomenon. Catheterizationand Cardiovascular Diagnosis, 39:1-6, 1996.
3. Del Campo, C, and Sherman, J. Tricuspid Valve Replacement: Results Comparing Mechanicaland Biological Prostheses. Ann Thoracic Surg 69:1295,
2000.
4. Tovar, Eduardo A., Sherman, Jon R., et al. Aortoscopy: A Less Invasive Intraoperative Method toAssess the Aortic Valve. Ann Thoracic Surg 73:284-286,
2002.
5. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., Peter Rakovec, M.D. J. BenezetPenaranda, M.D., Jon R. Sherman, M.D., Todd J. Shelton,
M.S., Cathy Zeng, M.S., and PaulWang, M.D. for the CAPTURE Trial Investigators. Factors Inuencing
Pacemaker GeneratorLongevity: Results from the
Complete Automatic Pacing Threshold Utilization Recorded in theCAPTURE Trial. PACE 33:1020-1030, 2010.
Abstracts:
1. Sherman, J.R., and Weinberg, R.B. Serum Apolipoprotein A-IV and Lipoprotein Cholesterol inPatients Undergoing Total Parenteral Nutrition.
Gastroenterology, 92; 5(2): 1805, May 1987.
2. Hener,
K.D., and Sherman, J.R. et at. Predicting Peak Exercise Heart Rate From Age In CardiacPatients: Inuence
of Medications and Gender.
Medicine and Science in Sports and Exercise, 26Suppl; 5. S184, May 1994.
3. Lawrence S. Rosenthal, Ph.D., M.D., Stephen W. Mester, M.D., J. Benezet Penaranda, M.D.,Jon R. Sherman, M.D., Raymond Gendreau, M.D., Yves R.
Vandekerckhove, M.D.,Peter Rakovec, M.D., Jon Seltzer, M.S., Benjamin Rhodes, M.S., Michael Hull, M.S. Eect
of Post-Mode Switch Overdrive Pacing on
Atrial Tachyarrhythmia Average Daily Burden in LargeRandomized Trial. Heart Rhythm Society, May 2009.
CLINICAL TRIALS:
A Randomized, Double-Blind, Placebo-Controlled Study to compare the effects of Nabumetone 2g, Celecoxib 400mg and Ibuprofen 24 mg per day on Blood Pressure Control in patients with hypertension stabilized on Anti hypertension Therapy.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-findingStudy of Lercanidipine Hydrochloride in Patients with Essential Hypertension.
An Open-label Evaluation of the effectiveness of Micardis (Telmisartan) on Blood Pressure Controland Quality of Life in Patients with Essential Hypertension.
A phase IIIb, randomized, open-label trial with 3 parallel groups: full dose TNK-tPA together with heparin sodium; full dose TNK-tPA together with Enoxaparin; half doseTNK-tPA together with Abciximab and heparin sodium in patients with acute myocardial infarction.
A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCL vs.Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA 1).
A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous Dosing Regimens of h5Gl.l-scFv in Patients with Acute Myocardial Infarction Undergoing Thrombolytic Reperfusion Therapy.
A Randomized, Double-Blind, Placebo-Controlled Trial of Two Intravenous DosingRegimens ofh5G l.l-scFv in Patients with Acute Myocardial Infarction UndergoingPercutaneous Transluminal Coronary Angioplasty Reperfusion Therapy.
An Open-Label, Long-Term, Safety Study ofRanolazine SR for Chronic Stable AnginaPectoris at Doses of 500 mg, 750 mg and 1000 mg Twice a Day Administered inCombination with Background Anti-Anginal Therapy (CVT-3034).
A Double-Blind, Randomized, Stratified, Placebo-Controlled, Parallel Study of Ranolazine SR at Doses of 750 mg Twice a Day and 1000 mg Twice a Day in Combination with Other Anti-Anginal Medications in Patients with Chronic Stable Angina Pectoris.
A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of WeeklyAzithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposureto C. Pneumoniae.
A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the ClinicalEfficacy and Tolerability of Early Treatment with Simvastatin 40 mg Daily for 30 Days,Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary
Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin, and in Optimally-Treated STElevation Acute Coronary Syndrome Patients.
A Multi-center, Randomized, Double-Blind, Placebo-controlled Study of the Effects on Blood Pressure ofTreatment with Nebivolol or Hydrochlorothiazide Alone and in Combination in Subjects with Mild toModerate Systemic Hypertension.
A Multicenter, Double-Blind, Randomized, Parallel, 28-week Study to Evaluate the Efficacy and Safetyof Simvastatin 80mg/day versus Atorvastatin 80mg/day in patients with Hypercholesterolemia (CHESScomparative HDL Efficacy and Safety Study).
Omapatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE)A Multicenter, Randomized, Double-Blind, Placebo-controlled, dose-ranging study of the long term (12weeks) Hemodynamic Effects, Safety, and Tolerability of study medication, a selective Endothelin-AReceptor Antagonist, in the Treatment of Heart Failure.
Study of the Costs Associated with the Use of the ACS Multi-link TristarrM Coronary Stent SystemCompared to Costs Associated with the Use of Other Stent Systems.
Effects of Oral N0-1886 on Lipoproteins in Subjects with Type II Diabetes Mellitus Who areReceiving Statin Therapy.
A Multicenter, randomized, controlled study in which patients are assigned in 1:1Proportions to use ofTRAPTM VFS device or control group without use of system.Determine the effectiveness of the TRAP VFS in providing distal embolizationProtection in coronary SVG intervention with PTCA and/or stenting.
Silent Atrial Fibrillation Detection with Stored EGMs (SAFE) Study. A Guidant U.S. MulticenterClinical Field Following Study. "Incidence of Asymptomatic Atrial Fibrillation in Bradycardia Patientswith Sick Sinus Syndrome."
A Phase III Randomized, Parallel, Double-Blind, Multicenter, Placebo-controlled Study of the Effect ofPexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary ArteryBypass Graft (CABG) Surgery with Cardiopulmonary Bypass.
Synergistic Effects of Risk Factors of Sudden Cardiac Death (SERF) Study. A Guidant MulticenterClinical Application Research Field Following Study.
Value of Electronically Recorded and Interrogated Follow-up via lPG Exported Data (VERIFIED). AMedtronic Pacemaker Registry.
Reported Atrial Fibrillation and Inappropriate Mode Switch in Sick Sinus Syndrome Patients (RARE)study. St. Jude Medical.
Clinical Observations on Usage, Learning and Trends (CONSULT) Kappa Pacemaker Program.Medtronic.
Limiting Chronotropic Incompetence for Pacemaker Recipients (LIFE) Study. Guidant.Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias (AWARE). St. JudeMedical.
Complete Automatic Pacing Threshold Utilization Recorded by EnPulse (CAPTURE) Clinical Study:A One-to-one Randomized, Multicenter, Prospective Study in Which Patients Receiving New EnPulsePacemaker Implants will be Randomized to Routine Manual Follow-up and Follow-up Using theAutomatic Features. Medtronic.
Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy andSafety of Two Blinded Doses of Dabigatran Etixilate with Open Label Warfarin for the Prevention ofStroke and Systemic Embolism in Patients with Non-Valvular AtrialFibrillation: Prospective, Multi-Centre, Parallel-Group Non-Inferiority Trial (RE-LY Study).Boehringer lngelheim Pharmaceuticals, Inc.
TREXIMET -Phase IIIb study to evaluate the efficacy and safety of a range of doses of a combinationproduct containing Sumatriptan and Naproxen Sodium for the acute treatment of migraine in adolescentmigrainers ages 12 through 17. GSK Adolescent Migraine Study.
A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Renal Impairment.
A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety andTolerance of Regadenoson in Subjects with Asthma or Chronic Obstructive Pulmonary Disease(COPD).